JP2014506579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506579A5 JP2014506579A5 JP2013553601A JP2013553601A JP2014506579A5 JP 2014506579 A5 JP2014506579 A5 JP 2014506579A5 JP 2013553601 A JP2013553601 A JP 2013553601A JP 2013553601 A JP2013553601 A JP 2013553601A JP 2014506579 A5 JP2014506579 A5 JP 2014506579A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- item
- acid sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000002249 Diabetes Complications Diseases 0.000 claims description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000001280 Prediabetic State Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000003914 insulin secretion Effects 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 231100000019 skin ulcer Toxicity 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 208000001288 gastroparesis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 34
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441748P | 2011-02-11 | 2011-02-11 | |
| US61/441,748 | 2011-02-11 | ||
| PCT/US2012/024684 WO2012109561A2 (en) | 2011-02-11 | 2012-02-10 | Peptide compositions and methods for treating patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016108514A Division JP6412897B2 (ja) | 2011-02-11 | 2016-05-31 | トリペプチド組成物および糖尿病を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506579A JP2014506579A (ja) | 2014-03-17 |
| JP2014506579A5 true JP2014506579A5 (enExample) | 2015-04-02 |
| JP5946473B2 JP5946473B2 (ja) | 2016-07-06 |
Family
ID=45852697
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553601A Active JP5946473B2 (ja) | 2011-02-11 | 2012-02-10 | トリペプチド組成物および糖尿病を治療する方法 |
| JP2016108514A Active JP6412897B2 (ja) | 2011-02-11 | 2016-05-31 | トリペプチド組成物および糖尿病を治療する方法 |
| JP2018064465A Withdrawn JP2018131446A (ja) | 2011-02-11 | 2018-03-29 | トリペプチド組成物および糖尿病を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016108514A Active JP6412897B2 (ja) | 2011-02-11 | 2016-05-31 | トリペプチド組成物および糖尿病を治療する方法 |
| JP2018064465A Withdrawn JP2018131446A (ja) | 2011-02-11 | 2018-03-29 | トリペプチド組成物および糖尿病を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8664177B2 (enExample) |
| EP (1) | EP2683393B1 (enExample) |
| JP (3) | JP5946473B2 (enExample) |
| CN (2) | CN105617351A (enExample) |
| AU (1) | AU2012214283B2 (enExample) |
| CA (1) | CA2827029C (enExample) |
| DK (1) | DK2683393T3 (enExample) |
| ES (1) | ES2673672T3 (enExample) |
| HU (1) | HUE038787T2 (enExample) |
| MX (1) | MX353301B (enExample) |
| WO (1) | WO2012109561A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2683393B1 (en) | 2011-02-11 | 2018-04-11 | The Regents of The University of Michigan | Tripeptide compositions and their use for treatment of diabetes |
| US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
| US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
| US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
| US20180074053A1 (en) * | 2015-04-03 | 2018-03-15 | Zhongmin Ma | Treatment of diabetes using agonists of the mas-related gpcr d |
| KR101909052B1 (ko) * | 2017-02-09 | 2018-10-17 | 강원대학교산학협력단 | 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물 |
| WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Vaccine compositions and methods of using the same |
| JP7068942B2 (ja) * | 2018-06-25 | 2022-05-17 | サンスター株式会社 | トリペプチド含有組成物 |
| KR20210043588A (ko) * | 2018-08-10 | 2021-04-21 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
| CA3190437A1 (en) * | 2020-08-18 | 2022-02-24 | The Regents Of The Universtiy Of Michigan | N-acyl amino acid products and uses |
| CN115252758A (zh) * | 2022-08-16 | 2022-11-01 | 中国科学院南海海洋研究所 | 线性小分子肽类似物在制备抗肥胖和降糖药物中应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL275394A (enExample) | 1961-02-28 | |||
| AU426743B2 (en) | 1967-09-21 | 1972-07-21 | MONASH UNIVERSITY, and ICI AUSTRALIA LIMITED | Processes forthe production of peptides and proteins |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| JPH04149139A (ja) * | 1990-10-12 | 1992-05-22 | Nippon Steel Corp | 血糖降下剤 |
| SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6069129A (en) * | 1998-03-13 | 2000-05-30 | Mrs, Llc | Elastin derived composition and method of using same |
| WO2000068695A2 (en) | 1999-05-12 | 2000-11-16 | Univ Oklahoma State | Reagent and process for peptide/protein differentiation using circular dichroism detection |
| AU2001275018B2 (en) | 2000-05-30 | 2008-04-03 | Connective Tissue Imagineering Llc | Composition and method for enhancing elasticity of tissue |
| SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| WO2002020769A1 (en) | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
| CA2421200A1 (en) | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Adenoviral targeting and manipulation of immune system response using targeting peptides |
| GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
| FI114710B (fi) * | 2001-03-12 | 2004-12-15 | Ctt Cancer Targeting Tech Oy | Leukosyytti-integriinien uusia peptidiligandeja |
| EP1497314A4 (en) | 2001-09-07 | 2007-10-10 | Univ Texas | COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS |
| WO2003024995A1 (en) * | 2001-09-19 | 2003-03-27 | Tripep Ab | Molecules that block viral infectivity and methods of use thereof |
| WO2003035028A1 (en) | 2001-10-19 | 2003-05-01 | Nektar Therapeutics | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| JP2007522246A (ja) | 2004-02-12 | 2007-08-09 | ネクター セラピューティクス | インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法 |
| WO2005115457A2 (en) | 2004-05-10 | 2005-12-08 | University Of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
| US20090221505A1 (en) * | 2004-11-16 | 2009-09-03 | Mikhail Kolonin | Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display |
| WO2006108211A1 (en) | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| GB0601950D0 (en) | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
| EP2047848A4 (en) * | 2006-07-05 | 2010-06-09 | Univ Tokyo | METHOD FOR THE TREATMENT OF GENETIC DISEASES BASED ON A NONSENSE MUTATION |
| US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| CZ298945B6 (cs) | 2006-09-18 | 2008-03-19 | Zentiva, A. S. | Polymerní lécivo a zpusob jeho výroby |
| WO2009026614A1 (en) * | 2007-08-24 | 2009-03-05 | Dia-B Tech Limited | Hypoglycaemic tripeptide and methods of use thereof |
| KR100947547B1 (ko) * | 2009-07-23 | 2010-03-12 | 월드웨이(주) | 실크 펩타이드를 유효성분으로 하는 당뇨 치료 또는 예방용 조성물 |
| EP2683393B1 (en) | 2011-02-11 | 2018-04-11 | The Regents of The University of Michigan | Tripeptide compositions and their use for treatment of diabetes |
-
2012
- 2012-02-10 EP EP12709416.7A patent/EP2683393B1/en active Active
- 2012-02-10 ES ES12709416.7T patent/ES2673672T3/es active Active
- 2012-02-10 JP JP2013553601A patent/JP5946473B2/ja active Active
- 2012-02-10 US US13/371,042 patent/US8664177B2/en active Active
- 2012-02-10 CN CN201610034403.7A patent/CN105617351A/zh active Pending
- 2012-02-10 WO PCT/US2012/024684 patent/WO2012109561A2/en not_active Ceased
- 2012-02-10 DK DK12709416.7T patent/DK2683393T3/en active
- 2012-02-10 HU HUE12709416A patent/HUE038787T2/hu unknown
- 2012-02-10 CN CN201280008561.5A patent/CN103458911B/zh active Active
- 2012-02-10 AU AU2012214283A patent/AU2012214283B2/en active Active
- 2012-02-10 MX MX2013009223A patent/MX353301B/es active IP Right Grant
- 2012-02-10 CA CA2827029A patent/CA2827029C/en active Active
-
2013
- 2013-11-22 US US14/087,247 patent/US9062093B2/en active Active
-
2016
- 2016-05-31 JP JP2016108514A patent/JP6412897B2/ja active Active
-
2018
- 2018-03-29 JP JP2018064465A patent/JP2018131446A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506579A5 (enExample) | ||
| CA2729938A1 (en) | New insulin analogues of prolonged activity | |
| DK2683393T3 (en) | TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES | |
| AU2016232448B2 (en) | Treatment type 2 diabetes mellitus patients | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| CN110087666B (zh) | 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 | |
| CA2543507A1 (en) | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions | |
| Robinson et al. | Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec | |
| CN104031141A (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| Toldra Filella | European Association for the Study of Diabetes (EASD)-54th Annual Meeting. Berlin, Germany-October 2-5, 2018 | |
| US20230081034A1 (en) | Dosing regimen of glp-1 | |
| WO2024261580A1 (en) | Glp-1 analog for use in the treatment of metabolic disorders | |
| HK40083623A (en) | Dosing regimen of glp-1 | |
| US20090233851A1 (en) | Insulin Resistance Improver | |
| Joshi | Role of insulin in type 2 diabetes | |
| BR112017018388B1 (pt) | Uso de combinação farmacêutica para o controle da glicemia em indivíduo com diabetes mellitus tipo 2 | |
| HK1244216B (en) | Treatment of type 2 diabetes mellitus patients | |
| NZ614080B2 (en) | Tripeptide compositions and methods for treatment of diabetes |